NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $23.75 -0.02 (-0.08 %) (As of 07/20/2018 04:00 PM ET)Previous Close$23.77Today's Range$23.49 - $24.0152-Week Range$7.12 - $24.20Volume518,100 shsAverage Volume1.49 million shsMarket Capitalization$2.50 billionP/E Ratio-22.20Dividend YieldN/ABeta1.98 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB for treating breast and lung cancer; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada. Receive SPPI News and Ratings via Email Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:SPPI CUSIP84763A10 Webwww.sppirx.com Phone702-835-6300 Debt Debt-to-Equity RatioN/A Current Ratio2.97 Quick Ratio2.91 Price-To-Earnings Trailing P/E Ratio-22.20 Forward P/E Ratio-26.10 P/E GrowthN/A Sales & Book Value Annual Sales$128.37 million Price / Sales19.25 Cash FlowN/A Price / CashN/A Book Value$3.49 per share Price / Book6.81 Profitability EPS (Most Recent Fiscal Year)($1.07) Net Income$-91,240,000.00 Net Margins-64.39% Return on Equity-29.47% Return on Assets-19.00% Miscellaneous Employees215 Outstanding Shares104,060,000Market Cap$2,500.44 Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions What is Spectrum Pharmaceuticals' stock symbol? Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI." How were Spectrum Pharmaceuticals' earnings last quarter? Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its quarterly earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.19. The biotechnology company had revenue of $30.50 million for the quarter, compared to the consensus estimate of $25.68 million. Spectrum Pharmaceuticals had a negative return on equity of 29.47% and a negative net margin of 64.39%. The company's revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.14) earnings per share. View Spectrum Pharmaceuticals' Earnings History. What price target have analysts set for SPPI? 4 brokers have issued 12 month target prices for Spectrum Pharmaceuticals' shares. Their predictions range from $25.00 to $33.00. On average, they anticipate Spectrum Pharmaceuticals' stock price to reach $29.00 in the next year. This suggests a possible upside of 22.1% from the stock's current price. View Analyst Ratings for Spectrum Pharmaceuticals. What is the consensus analysts' recommendation for Spectrum Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Spectrum Pharmaceuticals' key competitors? Some companies that are related to Spectrum Pharmaceuticals include Beigene (BGNE), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), FibroGen (FGEN), Loxo Oncology (LOXO), United Therapeutics (UTHR), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Dr.Reddy's Laboratories (RDY) and Ligand Pharmaceuticals (LGND). Who are Spectrum Pharmaceuticals' key executives? Spectrum Pharmaceuticals' management team includes the folowing people: Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 60)Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 50)Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 42)Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor RelationsMr. Keith M. McGahan J.D., L.L.M., Sr. VP & Chief Legal Officer Has Spectrum Pharmaceuticals been receiving favorable news coverage? News stories about SPPI stock have trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spectrum Pharmaceuticals earned a news impact score of 0.11 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 47.12 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days. Who are Spectrum Pharmaceuticals' major shareholders? Spectrum Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.15%), Bank of Montreal Can (0.14%), Municipal Employees Retirement System of Michigan (0.03%), Fox Run Management L.L.C. (0.02%), Ballentine Partners LLC (0.02%) and Amalgamated Bank (0.02%). Company insiders that own Spectrum Pharmaceuticals stock include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals. Which major investors are selling Spectrum Pharmaceuticals stock? SPPI stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Bank of Montreal Can, Ballentine Partners LLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Insider Buying and Selling for Spectrum Pharmaceuticals. Which major investors are buying Spectrum Pharmaceuticals stock? SPPI stock was acquired by a variety of institutional investors in the last quarter, including Hartford Investment Management Co., Fox Run Management L.L.C. and Amalgamated Bank. View Insider Buying and Selling for Spectrum Pharmaceuticals. How do I buy shares of Spectrum Pharmaceuticals? Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Spectrum Pharmaceuticals' stock price today? One share of SPPI stock can currently be purchased for approximately $23.75. How big of a company is Spectrum Pharmaceuticals? Spectrum Pharmaceuticals has a market capitalization of $2.50 billion and generates $128.37 million in revenue each year. The biotechnology company earns $-91,240,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Spectrum Pharmaceuticals employs 215 workers across the globe. How can I contact Spectrum Pharmaceuticals? Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected] MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 310 (Vote Outperform)Underperform Votes: 211 (Vote Underperform)Total Votes: 521MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: What is a closed-end mutual fund (CEF)?